FDA Panel Narrowly Endorses AtriCure’s Synergy For A-Fib Ablation
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Circulatory System Devices panel narrowly endorsed an expanded indication last week for AtriCure’s Synergy ablation system to treat certain types of atrial fibrillation during open-heart surgery, despite concerns over safety issues and limited data.